Insulin Receptor Gene Mutations in Iranian Patients with Type II Diabetes Mellitus

Bahram Kazemi1*, Negar Seyed1, Elham Moslemi2, Mojgan Bandehpour2, Maryam Bikhof Torbati3, Navid Saadat4, Akram Eidi2, Elham Ghayoor1 and Fereydoun Azizi4

1Cellular and Molecular Biology Research Center, Shahid Beheshti University, M.C., Tehran; 2Islamic Azad University of Iran, Science and Research Campus, Tehran; 3Islamic Azad University, Shahre Rey Branch, Tehran; 4Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University, M.C., Tehran, Iran

Received 24 June 2008; revised 16 May 2009; accepted 18 May 2009

ABSTRACT

Background: Patients with diabetes mellitus type II suffer from hyperglycemia because they are not able to use the insulin that they produce, often due to inadequate function of insulin receptors. There are some evidences that this deficiency is inherited in a dominant autosomal manner and leads to the malfunction of the pancreatic beta cells resulting in insulin excretion disorders. In this study, we sought to identify mutations in the insulin receptor (INSR) gene, which can cause insulin resistance in type II diabetic patients.

Methods: DNA was extracted from peripheral blood cells of the patients (n = 128) diagnosed with type II diabetes. All 22 exons of the INSR gene of the patients were analyzed for mutations running PCR, conformation-sensitive gel electrophoresis and DNA sequencing, consecutively.

Results: Approximately 26% of the patients had genetic mutations; however, most of them were not reported. These mutations include exon 2 (His171Asn, Ile172Ser, Cys196Ser and Ser210Arg), exon 3 (Gly227Asp and Gly232Ser), exon 8 (Thr543Ser), exon 9 (a heterozygote was observed with no change in phenylalanine at position 669), exon 13 (two heterozygotes: Arg890Pro with Asn865 remaining unchanged), exon 14 (Ala906Gly and Pro918Trp with Arg902 unchanged), exon 17 (Val1086Glu) and exon 19 (His1157Gln with Thr1172 unchanged).

Conclusion: The lack of similar mutation records in literature and genetic data banks may suggest a geographic pattern for these INSR gene variants in our population.

Keywords: Diabetes type II, Insulin resistance, PCR, Conformation-sensitive gel electrophoresis (CSGE), Iran

INTRODUCTION

Patients with diabetes mellitus type II, also known as non-insulin-dependent diabetes mellitus (NIDDM) [1] suffer from hyperglycemia because they are not able to use the insulin produced at their body, often due to inadequate function of insulin receptors. This affliction has many health effects such as blindness [2]. Symptoms generally start after the age of 40, thus it is also called adult diabetes. NIDDM is more often a problem in overweighting people after the age of 35 with high blood insulin concentrations. About 85-90% of diabetics over the age of 40, are diagnosed as type II [2]. Racial and geographical differences in the distribution of diabetes type II indicate the heterogeneity of the disease [3]. Although it appears to be familial, the inheritance pattern of NIDDM is already unknown and suspected as dominant autosomal [4]. Such resistance leads to the malfunctioning of the pancreatic beta cells resulting in insulin excretion disorders [5].

In 1988, Kadowaki et al. [6] brought up the question of whether mutations in the insulin receptor (INSR) gene, located on chromosome 19 (p13.3-p13.2), account for the insulin resistance in patients with NIDDM. Taira et al. [7] reported cases of NIDDM carrying mutations at INSR. These mutations end in receptors with slightly decreased kinase activity or affinity for insulin. With such cases, environmental factors including obesity may trigger the onset of diabetes. A reduction in the number of insulin receptors in obese people is also
now known to cause resistance to insulin [7]. Proper
diet and normal blood sugar levels may in turn
improve the insulin excretion capacity by improving
the function of the receptors [7].

The aim of this research was to identify any
mutations in each of the 22 exons of the INSR gene
in Iranian patients diagnosed with NIDDM.

MATERIALS AND METHODS

Patients and sampling. We selected subjects
diagnosed with NIDDM based on the following
inclusion criteria: 40 years old or older at the onset
of disease, no history of diabetic ketoacidosis
(DKA), overweight (BMI ≥ 20 kg/m²) and NIDDM
cases in at least one of the first relatives. Subjects
with any of the following exclusion criteria were not
entered in the study: personal history of DKA, BMI ≤ 20 kg/m² or significant idiopathic weight loss
during illness (without hyperthyroidism, digestion
syndrome, malignancy, and so forth), any pancreatic
illness (chronic, trauma, neoplasm, hemo-
chromatosis), drug dependency (thyroid hormones,
interferon, glucocorticoid and nicotine), infectious
disease (such as congenital rubella or cytomegalovirus virus), genetic syndromes (such as
Duane, Klinefelter or Turner), history of gestational
diabetes. For analysis of exon 8, non-diabetic
subjects were tested as controls. Patients (n = 128)
visited by an endocrinologist and diagnosed with
type II diabetes were selected based on the above
mentioned inclusion criteria and referred to the
Cellular and Molecular Biology Research Center of
Shahid Beheshti University (Tehran, Iran). All the
patients signed consent and then peripheral blood (5
cc, EDTA) was collected. The samples were kept
frozen until use.

DNA extraction. DNA was extracted from
peripheral blood by the sodium perchlorate method.
Briefly, blood (500 µl) was suspended in 1 ml of
lysis buffer (10 mM Tris-HCl, pH 8, 0.1 mM EDTA,
0.15 M NaCl, 0.5% Triton X-100) and centrifuged at
8000 ×g for 5 min. Then, sodium perchlorate
(100 µl, 4 M), SDS (10 µl, 10%) and TE buffer (400
µl; 10 mM Tris, 1 mM EDTA) and NaCl (100 µl, 5N)
were added to the pellet. This solution was
mixed and centrifuged at 12,000 ×g for 10 min. The
supernatant was transferred to a new tube and the
DNA was precipitated by alcohol and dissolved in
100 µl dH2O.

Primer design. For each exon, we designed a pair
of primers (Table 1) that anneal to the respective
exon and 50 to 100 nucleotides of flanking introns.
PCR products were subject to conformation-
sensitive gel electrophoresis (CSGE) for mutation
detection. It must be mentioned here that the
mutation detection in the first and last bases of PCR
product is not reliable.

PCR amplification. A total of 50 µl reaction
volume in each tube contained 200 ng genomic
DNA, 0.2 mM dNTP, 1.5 mM MgCl2, 40 pmol each
of forward and reverse primers, 1× PCR buffer, 1.25
unit of Taq DNA polymerase (CinnaGen, Iran).
Terminal cycle conditions consisted of initial
denaturation at 94°C for 5 min, followed by 30
cycles including denaturation at 94°C for 30 s,
annealing at exon primer specific temperature for 60
s and extension at 72°C for 30 s. The final
incubation was also included at 72°C for 5 min [8].

PCR product electrophoresis. The PCR products
were electrophoresed in 1.5% agarose gel. The gel
was stained with ethidium bromide, and the bands
were visualized under UV transillumination and
photographed [9].

Scanning of PCR products by CSGE. All the PCR
products were analyzed by CSGE for any possible
mutation [10]. A 10% polyacrylamide gel containing
99:1 acrylamide (Sigma-Aldrich, St. Louis, MO,
USA) was used as the base of electrophoresis to
Bis(acryloyl)piperazine (BAP); Fluka, Switzerland),
10% ethylene glycol (Sigma, Germany), 15%
formamide (Gibco, Carlsbad, CA, USA), 0.1%
ammonium per sulfate (Sigma-Aldrich, Germany),
0.07% N,N,NV,NV-tetra methyl ethylene diamine
(Sigma-Aldrich, Germany) and 0.5× TTE buffer (44
mM Tris, 14.5 mM taurine, 0.1 mM EDTA buffer,
pH 9.0). The gel was loaded onto a vertical cast
preparation of standard gel apparatus (Bio-Rad
Laboratories, Hercules, CA, USA) with 18-cm glass
plates. A pre-run for 30 min at 30 mA with 0.5×
TTE electrophoresis buffer did set the gel construct
at its optimal status. PCR products were first heated
up to 98°C for 5 min to be denatured completely and
then were cooled down to 65°C for 30 min to let the
strands to re-anneal again. PCR products were
mixed with 5 µl loading buffer (30% glycerol, 0.25%
bromophenol blue and 0.25% xylene cyanol
FF) and then loaded onto the gel, and elec
trophoresed at room temperature at 40 mA for 4 h.

http://IBJ.pasteur.ac.ir
Table 1. Primers for amplification of INSR gene.

<table>
<thead>
<tr>
<th>Exon number</th>
<th>Primer sequence</th>
<th>Size of PCR Product (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>INSR1 F 5’ - GAG AGC CGA GAG ACA GTC CCG G– 3’</td>
<td>500</td>
</tr>
<tr>
<td>2</td>
<td>INSR1 R 5’ - ATT TGT GCT TGG GTG GGG TCC TCT TC T– 3’</td>
<td>653</td>
</tr>
<tr>
<td>3</td>
<td>INSR2 F 5’ - CCC CTA CCT AAT GAC CAT TT T– 3’</td>
<td>472</td>
</tr>
<tr>
<td>4</td>
<td>INSR2 R 5’ - CCC TCT CTC TCT CTC TC T– 3’</td>
<td>310</td>
</tr>
<tr>
<td>5</td>
<td>INSR3 F 5’ - AGA CCA TCC TAA AAG TGC TG G– 3’</td>
<td>500</td>
</tr>
<tr>
<td>6</td>
<td>INSR3 R 5’ - CTA CAC TAG TCA ATG CCA AT T– 3’</td>
<td>593</td>
</tr>
<tr>
<td>7</td>
<td>INSR4 F 5’ - CCA GCC AAC AGC CAG CC– 3’</td>
<td>472</td>
</tr>
<tr>
<td>8</td>
<td>INSR4 R 5’ - CTA CTC CCA AGA CA CAG CC G– 3’</td>
<td>310</td>
</tr>
<tr>
<td>9</td>
<td>INSR5 F 5’ - AGA AGA GTG AAA TAT GT G– 3’</td>
<td>259</td>
</tr>
<tr>
<td>10</td>
<td>INSR5 R 5’ - CCT AAT AAC GTG TGG G– 3’</td>
<td>329</td>
</tr>
<tr>
<td>11</td>
<td>INSR6 F 5’ - ACC ATC ATT CAA GCC AAT TGG G– 3’</td>
<td>293</td>
</tr>
<tr>
<td>12</td>
<td>INSR6 R 5’ - CTA CAC TAG TCA ATG CCA AT T– 3’</td>
<td>310</td>
</tr>
<tr>
<td>13</td>
<td>INSR7 F 5’ - TGA CAG AGA AGA AGA GC G– 3’</td>
<td>330</td>
</tr>
<tr>
<td>14</td>
<td>INSR7 R 5’ - TGA CAG AGA AGA AGA GC G– 3’</td>
<td>330</td>
</tr>
<tr>
<td>15</td>
<td>INSR8 F 5’ - AGA TGC CCT TCA CCT CCA AGA CA G– 3’</td>
<td>359</td>
</tr>
<tr>
<td>16</td>
<td>INSR8 R 5’ - AGA TGC CCT TCA CCT CCA AGA CA G– 3’</td>
<td>359</td>
</tr>
<tr>
<td>17</td>
<td>INSR9 F 5’ - CTC GTC GTC TGA AA GAC CTT CTA G– 3’</td>
<td>293</td>
</tr>
<tr>
<td>18</td>
<td>INSR9 R 5’ - CTC GTC GTC TGA AA GAC CTT CTA G– 3’</td>
<td>293</td>
</tr>
<tr>
<td>19</td>
<td>INSR10 F 5’ - ATG TGT ATG TGT GTT CAG CCG GA C– 3’</td>
<td>310</td>
</tr>
<tr>
<td>20</td>
<td>INSR10 R 5’ - CAA ACA GCC AAT TGG CA G– 3’</td>
<td>309</td>
</tr>
<tr>
<td>21</td>
<td>INSR11 F 5’ - TGT TCT GAT GTA GCT CCG GA C– 3’</td>
<td>197</td>
</tr>
<tr>
<td>22</td>
<td>INSR11 R 5’ - CAA ACA GCC AAT TGG CA G– 3’</td>
<td>197</td>
</tr>
<tr>
<td>23</td>
<td>INSR12 F 5’ - TAT TCT GAC GTG TCA CCT TT T– 3’</td>
<td>402</td>
</tr>
<tr>
<td>24</td>
<td>INSR12 R 5’ - AAG TCA GCC TGG ATG TCC CA T– 3’</td>
<td>402</td>
</tr>
<tr>
<td>25</td>
<td>INSR13 F 5’ - TGT GAT CTC ATC CAA GAG TT T– 3’</td>
<td>249</td>
</tr>
<tr>
<td>26</td>
<td>INSR13 R 5’ - ACT CTG AAG GGG CAT GCT GA T– 3’</td>
<td>249</td>
</tr>
<tr>
<td>27</td>
<td>INSR14 F 5’ - TGG CTC TCT TCT TCT TCT TC T– 3’</td>
<td>210</td>
</tr>
<tr>
<td>28</td>
<td>INSR14 R 5’ - CTC GTC TCT TCT TCT TCT TC T– 3’</td>
<td>210</td>
</tr>
<tr>
<td>29</td>
<td>INSR15 F 5’ - TTC TAT TCT TCT CTA CCT TCC T– 3’</td>
<td>140</td>
</tr>
<tr>
<td>30</td>
<td>INSR15 R 5’ - GCA CAC TCA GCC CTG TAA TCT G– 3’</td>
<td>140</td>
</tr>
<tr>
<td>31</td>
<td>INSR16 F 5’ - CCA TGA GAA TCT CAA GCT AAC G– 3’</td>
<td>132</td>
</tr>
<tr>
<td>32</td>
<td>INSR16 R 5’ - CCA TGA GAA TCT CAA GCT AAC G– 3’</td>
<td>132</td>
</tr>
<tr>
<td>33</td>
<td>INSR17 F 5’ - CTA CAG ACA CA GAC CAC AG T– 3’</td>
<td>480</td>
</tr>
<tr>
<td>34</td>
<td>INSR17 R 5’ - TAG GAG GAT ACA GCC TGG GCT G– 3’</td>
<td>480</td>
</tr>
<tr>
<td>35</td>
<td>INSR18 F 5’ - CCT GGT GAG TCG AAT CAC GG G– 3’</td>
<td>227</td>
</tr>
<tr>
<td>36</td>
<td>INSR18 R 5’ - GAG GAG GCC AGG AGC GGG TG T– 3’</td>
<td>227</td>
</tr>
<tr>
<td>37</td>
<td>INR 19 F 5’ - GAT CCC AGT GCT GCT GAA AC G– 3’</td>
<td>250</td>
</tr>
<tr>
<td>38</td>
<td>INR 19 R 5’ - ACC TGG CTT GCG TGG TTA TG G– 3’</td>
<td>250</td>
</tr>
<tr>
<td>39</td>
<td>INR 20 F 5’ - GGT GCT AGG ACC AAG GCT GA G– 3’</td>
<td>228</td>
</tr>
<tr>
<td>40</td>
<td>INR 20 R 5’ - GAA TTC AAG CCC AGC GTC CA A– 3’</td>
<td>228</td>
</tr>
<tr>
<td>41</td>
<td>INR 21 F 5’ - GTG GCT TAA GTG CTC T– 3’</td>
<td>330</td>
</tr>
<tr>
<td>42</td>
<td>INR 21 R 5’ - TAT GCA AAC ACA AAC ACA CC A– 3’</td>
<td>330</td>
</tr>
<tr>
<td>43</td>
<td>INR 22 F 5’ - GTG CAG GGA CAA GAG TGG GG G– 3’</td>
<td>873</td>
</tr>
<tr>
<td>44</td>
<td>INR 22 R 5’ - TTT GGT TTT TTT TTT CAA TTT G– 3’</td>
<td>873</td>
</tr>
</tbody>
</table>

The gel was stained with ethidium bromide (1 mg/ml) for 10 min and destained in dH2O for 10 min.

**Sequencing the suspected mutations.** PCR products of the samples with a suspected mutation, detected by CSGE method, were purified using a DNA extraction kit (Fermentas, Lithuania Cat. # K0513) and subjected to sequencing by the dideoxy chain-termination method [11].

http://IBJ.pasteur.ac.ir
RESULTS

The PCR products relevant to a few exons of insulin receptor gene are shown in Figure 1 along with DNA ladder marker. The mutations of exons 14, 15, 16 and 17 (tyrosine kinase domain) were determined by direct sequencing of the PCR product, while the rest was first screened through CSGE and then the suspected samples were submitted for sequencing. Any double-bond sample observed on the illuminated gel under UV light was suspected for mutation (Fig. 2). Because of the specific design of primers, we were able to discriminate the mutation existing on exon sequence or donor/acceptor or branch sites of the introns.

Screening of mutations by CSGE method. We detected mutations on the INS gene sequence of 33 (25.78%) of the 128 Iranian type II diabetes patients (Table 2). On exon 2 of four patients, we detected four mutations: at position 511 C→A, at position 514 T→G, at positions 586 and 628 T→A resulted in amino acid changes His 171 Asp, Ile 172 Ser, Cys 196 Ser, and Trp 628 Arg, respectively. On exon 3 of four patients, at position 694 G→C resulting in a Gly 232 Ser change. On exon 3 of four patients, at position 680 G→A resulting in a Gly 227 Asn change, establishing a recognition site for the PvuII restriction enzyme (CAGCTG), which was confirmed by restriction digestion with PvuII enzyme (data not shown). This enzyme does not

Fig. 1. Two percent of agarose gel electrophoresis of PCR product. (A) Lane 1, PCR product of exon 2 of insulin receptor gene; lane 2, 100 bp DNA ladder and lane 3, PCR product of exon 3 of insulin receptor gene. (B) Lane 1, PCR product of exon 11 of insulin receptor gene; lane 2, PCR product of exon 8 of insulin receptor gene; lane 3, PCR product of exon 10 of insulin receptor gene; lane 4, PCR product of exon 13 of insulin receptor gene and lane 5, 100 bp DNA ladder. (C) Lane 1, PCR product of exon 6 of insulin receptor gene; lane 2, PCR product of exon 12 of insulin receptor gene; lane 3, PCR product of exon 4 of insulin receptor gene and lane 4, 100 bp DNA ladder. (D) Lane 1, PCR product of exon 22 of insulin receptor gene insulin receptor gene and lane 2, 100 bp DNA ladder.

Fig. 2. CSGE electrophoresis of PCR product. Lane 1, PCR product of normal sample and lanes 2-4, PCR product of suspected ones.
Table 2. Mutations detected in the INSR gene of Iranian NIDDM patients, based on GenBank accession number M10051.

<table>
<thead>
<tr>
<th>GenBank accession number</th>
<th>Exon number/nucleotide position</th>
<th>Amino acid position</th>
<th>Nucleotide variation</th>
<th>Codon variation</th>
<th>Amino acid variation</th>
<th>Mutations Frequency</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>EF207606</td>
<td>2/511</td>
<td>171</td>
<td>C→A</td>
<td>CAC→AAC</td>
<td>His→Asn</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2/515</td>
<td>172</td>
<td>T→G</td>
<td>ATC→AGC</td>
<td>Ile→Ser</td>
<td>4</td>
</tr>
<tr>
<td>EF207605</td>
<td>2/586</td>
<td>196</td>
<td>T→A</td>
<td>TGC→AGC</td>
<td>Cys→Ser</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>EF207605</td>
<td>2/628</td>
<td>210</td>
<td>T→A</td>
<td>TGG→AGG</td>
<td>Trp→Arg</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>EU331144</td>
<td>3/679</td>
<td>227</td>
<td>G→A</td>
<td>GGC→AGC</td>
<td>Gly→Ser</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>EU331144</td>
<td>3/694</td>
<td>232</td>
<td>G→C</td>
<td>GGC→AGC</td>
<td>Gly→Ser</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>DQ333190</td>
<td>8/1627</td>
<td>543</td>
<td>A→T</td>
<td>ACG→TCG</td>
<td>Thr→Ser</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>EF207612</td>
<td>9/2007</td>
<td>669</td>
<td>C→C/T</td>
<td>TTC→TTT</td>
<td>Phe→Phe</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>EF207609</td>
<td>13/2595</td>
<td>865</td>
<td>C→C/T</td>
<td>AAC→AAT</td>
<td>Asp→Asp</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>EF207608</td>
<td>13/2669</td>
<td>890</td>
<td>G→G/C</td>
<td>CGA→CCA</td>
<td>Arg→Pro</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>DQ068255</td>
<td>14/2706</td>
<td>902</td>
<td>C→G</td>
<td>CGC→CGG</td>
<td>Arg→Arg</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>DQ068255</td>
<td>14/2717</td>
<td>906</td>
<td>C→G</td>
<td>GCT→GGT</td>
<td>Ala→Gly</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>EF025510</td>
<td>14/2752 and 2753</td>
<td>918</td>
<td>CC→TG</td>
<td>CCG→TGG</td>
<td>Pro→Trp</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>DQ311689</td>
<td>17/3257</td>
<td>1086</td>
<td>T→A</td>
<td>GTG→gAG</td>
<td>Val→Gln</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>EF207610</td>
<td>19/3471</td>
<td>1157</td>
<td>T→T/A</td>
<td>CAT→CAA</td>
<td>His→Gln</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>EF207610</td>
<td>19/3516</td>
<td>1172</td>
<td>T→T/G</td>
<td>ACT→ACG</td>
<td>Thr→Thr</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

normally have a recognition site on exon 3. On exon 8 of five patients, at position 1627 an A→T mutation resulted in a Thr 543 Ser change. In intron 9, mutations were detected in nucleotides 18 and 19 (AT→TG). On exon 9 of three patients, we observed a heterozygote C→C/T at position 2007, leaving Phe 669 unchanged. We also observed two heterozygote mutations on exon 13 of three patients. At position 2595 and 2669, nucleotides C and G were observed as C/T and C/G, respectively (Asp 865 Asp and Arg 890 Pro). On exon 14 of eight patients, C→G at positions 2706 and 2717 resulted in Arg 902 Arg and Ala 906 Gly, respectively. A missense mutation was found in exon 14: C at positions 2752 and 2753 (CCG→TGG) was replaced with T and G, respectively, resulting in Pro 918 Trp replacement (Fig. 3). Two heterozygotes were observed on exon...
Fig. 3. Chromatogram shows C at position 2752 and 2753 (CCC→TGG) were replaced with T and G on exon 14 of insulin receptor gene, replaced of proline 918 with tryptophan.

19 of two patients. Nucleotide T at positions 3471 and 3516 was detected as T/A and T/G, respectively (His 1157 Gln and Thr 1172 Thr). No changes were observed on other exon sequences.

Controls. We identified no modifications on the INSR gene in exon 8 in non-diabetic control subjects.

Sequencing. The sequences of the PCR products, suspected to have mutations by their kinetic patterns on the CSGE gel, were submitted to GenBank with the accession numbers as shown in Table 2. DQ333190, DQ311689, DQ068255, EF207605, EF207606, EF207608, EF207609, EF207610, EF207612, EU331144

DISCUSSION

It is estimated that up to 90% of the people with type II diabetes suffer from insulin resistance [12]. Both insulin secretion and insulin receptor action are under genetic control; therefore, mutation in either set of genes (for insulin secretion or insulin receptor action) could theoretically be the primary event in diabetes. Several INSR mutation studies have been carried out in order to improve new therapy for diabetic patients [13].

This study represents the first effort in Iran to perform a complete molecular analysis of all 22 exon sequences of the INSR gene in type II diabetic patients to identify mutations and compare the results to the mutations reported in other populations.

The genetic analysis of the insulin receptor started in 1983, but the first clinical report of a patient with defective INSR was recognized in 1975. In recent years, INSR mutations were found to cause resistance to insulin. In case of INSR gene mutations that change the function of the receptor, although normal insulin secretion continues, the receptor does not react to the existing insulin, indicating that the insulin signal pathway within the cell is either inactive or defective.

A number of researchers studied different mutations in the INSR gene and reported that such mutations do not result in type II diabetes. For example, Moller et al. [14] studied a 1611-bp segment of the glucose transporter II promoter gene using single-strand conformation-polymorphism analysis and direct sequencing in patients affected by type II diabetes in Denmark. They detected four mutations (Gly 471 Ala, Asp 149 Ala, Thr 122 Asp and Gly 447 Ala), though none of them contributed to the type II diabetes [14]. Hansen et al. [15] reported Met 326 Ile and Gly 1020 Ala in alpha subunit of P85 phosphatidylinositol 3 kinase in NIDDM, with no function in diabetes. They followed the Met 326 Ile mutation in the p85 alpha regulatory subunit of the phosphoinositide 3-kinase in 1190 Caucasian men for 20 years. Hansen et al. [15] also studied the relevant protein, and reported that this mutation had no relationship with type II diabetes and had no effect on the role of insulin [16]. On the other hand, there are some reports relating NIDDM to genomic mutations.

Hojlund et al. [25] reported missense mutation (Arg 1174 Gln) in tyrosine kinase domain of insulin receptor gene related to NIDDM. Accili et al. [26] detected a homozygote mutation (Val 382 Phe) in a family resistant to insulin; however, Roach et al. [27] reported Ser 323 Leu mutation in an insulin resistance patient.

Tyrosine kinase receptors are a family of receptors with a similar structure. They each have a tyrosine kinase domain (which phosphorylates proteins on tyrosine residues), a hormone binding domain, and a carboxyl terminal segment with multiple tyrosines for autophosphorylation. When hormone binds to the extracellular domain, the receptors aggregate. When the receptors aggregate, the tyrosine kinase domains phosphorylated the C terminal tyrosine residues [28]. The tyrosine kinase is attached to insulin hormone and its mutations are very important in patients.

We searched in the literature for each of the mutations found in the present study; however, no similar mutations have been reported in type II diabetes patients. Therefore, it is possible that these mutations could be specific for the Iranian population. More investigations are needed to determine the incidence of such mutations in Iranian patients, and more importantly, whether these mutations correlate with clinical signs and symptoms. We observed many novel mutations in our analysis of the insulin receptor gene of Iranian type II diabetes patients. The fact that these mutations have not been reported in studies performed in other countries suggests the possibility of a geographic pattern for these variants in the INSR gene.

ACKNOWLEDGMENTS

This study was supported by the Vice Chancellor for Research of Shahid Beheshti University, M.C. and Research Institute for Endocrine Sciences of Shahid Beheshti University, M.C. (Tehran, Iran). We appreciate the expertise and assistance of members of the Cellular and Molecular Biology Research Center.

REFERENCES


http://IBJ.pasteur.ac.ir


